- Home
- SSKN vs KZIA Comparison
SSKN vs KZIA Comparison
Compare SSKN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSKN
- KZIA
- Stock Information
- Founded
- SSKN 1989
- KZIA 1994
- Country
- SSKN United States
- KZIA Australia
- Employees
- SSKN N/A
- KZIA N/A
- Industry
- SSKN Medical/Dental Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SSKN Health Care
- KZIA Health Care
- Exchange
- SSKN Nasdaq
- KZIA Nasdaq
- Market Cap
- SSKN 8.9M
- KZIA 9.0M
- IPO Year
- SSKN 2005
- KZIA 1999
- Fundamental
- Price
- SSKN $1.70
- KZIA $8.05
- Analyst Decision
- SSKN Strong Buy
- KZIA Strong Buy
- Analyst Count
- SSKN 1
- KZIA 2
- Target Price
- SSKN $6.00
- KZIA $14.00
- AVG Volume (30 Days)
- SSKN 2.8M
- KZIA 18.7K
- Earning Date
- SSKN 08-13-2025
- KZIA 06-05-2025
- Dividend Yield
- SSKN N/A
- KZIA N/A
- EPS Growth
- SSKN N/A
- KZIA N/A
- EPS
- SSKN N/A
- KZIA N/A
- Revenue
- SSKN $32,848,000.00
- KZIA $1,549,158.00
- Revenue This Year
- SSKN N/A
- KZIA N/A
- Revenue Next Year
- SSKN $9.70
- KZIA $49.25
- P/E Ratio
- SSKN N/A
- KZIA N/A
- Revenue Growth
- SSKN 0.36
- KZIA 248983.08
- 52 Week Low
- SSKN $1.61
- KZIA $2.86
- 52 Week High
- SSKN $3.86
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- SSKN 43.89
- KZIA 50.39
- Support Level
- SSKN $1.61
- KZIA $7.52
- Resistance Level
- SSKN $3.86
- KZIA $8.39
- Average True Range (ATR)
- SSKN 0.36
- KZIA 0.66
- MACD
- SSKN 0.03
- KZIA 0.05
- Stochastic Oscillator
- SSKN 4.00
- KZIA 68.28
About SSKN Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.